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Abstract
Background: The ErbB receptor tyrosine kinases and nucleolin are major contributors to malignant transformation. Recently
we have found that cell-surface ErbB receptors interact with nucleolin via their cytoplasmic tail. Overexpression of ErbB1 and
nucleolin leads to receptor phosphorylation, dimerization and anchorage independent growth.
Methodology/Principal Findings: In the present study we explored the regions of nucleolin and ErbB responsible for their
interaction. Using mutational analyses, we addressed the structure–function relationship of the interaction between ErbB1
and nucleolin. We identified the ErbB1 nuclear localization domain as nucleolin interacting region. This region is important
for nucleolin-associated receptor activation. Notably, though the tyrosine kinase domain is important for nucleolin-
associated receptor activation, it is not involved in nucleolin/ErbB interactions. In addition, we demonstrated that the 212 c-
terminal portion of nucleolin is imperative for the interaction with ErbB1 and ErbB4. This region of nucleolin is sufficient to
induce ErbB1 dimerization, phosphorylation and growth in soft agar.
Conclusions/Significance: The oncogenic potential of ErbB depends on receptor levels and activation. Nucleolin affects
ErbB dimerization and activation leading to enhanced cell growth. The C-terminal region of nucleolin and the ErbB1 NLS-
domain mediate this interaction. Moreover, when the C-terminal 212 amino acids region of nucleolin is expressed with
ErbB1, it can enhance anchorage independent cell growth. Taken together these results offer new insight into the role of
ErbB1 and nucleolin interaction in malignant cells.
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Introduction
The ErbB subfamily of receptor tyrosine kinases (RTK) consists
of four receptors: epidermal growth factor receptor (EGFR,-
HER1,ErbB1), HER2 (ErbB2,neu), HER3 (ErbB3) and HER4
(ErbB4) [1–7]. These receptors are mediators of growth signals
and thus determine cell fate. They are cell surface allosteric
enzymes consisting of a single transmembrane domain that
separates the intracellular kinase domain from the extracellular
ligand-binding domain. Ligand binding to the ectodomain results
in allosteric alterations leading to receptor homo- or hetero-
dimerization, kinase activation, and trans-autophosphorylation [8–
10]. Subsequent tyrosine phosphorylation on residues within the
carboxyl terminal tail of the receptors enables the recruitment and
activation of signaling effectors containing Src homology 2 (SH2)
domain and phosphotyrosine binding (PTB) domain that will lead
to the initiation of various signaling cascades [11–13]. The ErbB
receptors are expressed in various tissues of epithelial, mesenchy-
mal and neuronal origin. Under normal physiological conditions,
activation of the ErbB receptors is controlled by the spatial and
temporal expression of their ligands, which are members of the
EGF family of growth factors [14]. Abnormal function of the ErbB
receptors and their ligands is involved in human cancer and
already serve as target for several cancer drugs [15].
Nucleolin is a ubiquitous expressed acidic phosphoprotein of
exponentially growing cells. It is involved mainly in the synthesis
and maturation of ribosomes [16]. Nucleolin is a nonhistone
nucleolar phosphoprotein, present mainly at the dense fibrillar and
granular regions of the nucleolus [17,18]. In nondividing cells,
degraded forms of various molecular sizes are predominantly
expressed due to auto degradation [19]. Hence, the protein
appears to be involved in essential aspects of transcriptional
regulation, cell proliferation, and growth [20,21]. Recently, it was
demonstrated that nucleolin is a multifunctional shuttling protein
present in nucleus, cytoplasm, and on the surface of some types of
cells [16,22,23]. It was also demonstrated that inhibition of cell-
surface nucleolin suppresses tumor growth and angiogenesis [24].
Inhibition of nucleolin activity results in cell growth inhibition
[25]. In addition, it was demonstrated in several studies that
AS1411 (or GROA), a quadruplex-forming oligonucleotide
aptamer, targets nucleolin and inhibits cancer cells growth
[26,27]. Also, it was demonstrated that inhibition of cell-surface
expressed nucleolin, by HB-19 pseudo peptide, suppresses tumor
growth and angiogenesis [24]. These effects of cell-surface
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glioma cell lines which also express high levels of ErbB receptors.
In our most recent study we identified nucleolin as an ErbB
receptors interacting protein [28]. This interaction on the cell
surface, leads to receptor dimerization and activation as well as to
colonies growth on soft agar [28]. We therefore suggested that the
cross talk between nucleolin and ErbB proteins may be related to
tumor growth.
Nucleolin protein contains several functional domains that
mediate its functions [29]. The N-terminal part contains
multiple phosphorylation sites and is rich in acidic amino acids.
The central part of nucleolin includes four RNA binding
domains (RBD) and the C-terminal part contains glycine and
arginine rich domain (termed RGG or GAR domain)
[16,30,31]. In the present study we demonstrate that ErbB1
juxtamembrane region (the nuclear localization sequence NLS),
which is important for ErbB1 kinase activation [32], is also
important for nucleolin-ErbB1 interaction and nucleolin-induced
ErbB1 dimerization and activation. In addition, we further
demonstrate that the 212 C-terminal amino acids of nucleolin
(RBD4 and GAR domains) are sufficient for cell surface
localization and for ErbB1 interaction and activation. Moreover,
the 212 C-terminal amino acids of nucleolin when expressed
with ErbB1, co localize to the cell membrane and enhance
colonies formation in soft agar.
Results
Analysis of ErbB1 domains responsible for nucleolin/
ErbB1 interaction
In our previous report we have demonstrated that nucleolin
interacts with the four ErbB receptors and that this interaction is
functional as it induces receptor activation in a ligand independent
manner [28]. In order to identify the receptor domain responsible
for the interaction with nucleolin several deletion mutants in the
cytoplasmic tail of the ErbB1 receptor were generated. The
scheme of the designed deletion mutants is presented in Figure 1A.
The mutants were examined for their ability to bind nucleolin by
co-immunoprecipitation. As shown in Figure 1B, only two mutants
failed to be precipitated by nucleolin; DCyt 1 and DNLS. These
results suggest that the region in ErbB1, important for nucleolin
binding, may be the ErbB1 nuclear localization sequence (NLS)
(RRRHIVRKRTLRR (amino acids 669–681)). This region is
known to regulate ErbB1 activity since it mediates the nuclear
localization of EGFR [33] as well as receptor kinase activation
[32].
Since the DCyt mutants lack phosphorylated tyrosine residues in
the cytoplasmic tail of the receptor they are not functional in
mediating signals. Nevertheless, it was important to examine
whether nucleolin can affect the DNLS mutant-mediated signals
and whether the DTK mutant that contains the cytoplasmic tail
(phosphorylation sites) and binds nucleolin can transmit signals
following co- expression. To determine whether nucleolin affects
ErbB1 or ErbB1 DNLS mutant tyrosine phosphorylation we co-
expressed ErbB1 or ErbB1 DNLS mutant and nucleolin in HEK-
293T cells. Indeed, when nucleolin was co-expressed with ErbB1 it
induced receptor phosphorylation even in the absence of EGF.
However, when ErbB1 DNLS mutant was co-expressed with
nucleolin no phosphorylation was detected even in the presence of
EGF (Figure 2A). Cross linking experiments confirm that EGF but
not nucleolin can induce dimerization of the ErbB1 DNLS
receptor mutant (Figure 2B). This result correlates with the finding
that ErbB1 DNLS mutant cannot interact with nucleolin.
Similarly, the ErbB1 mutant in the tyrosine kinase domain
(DTK) failed to undergo phosphorylation, when co-expressed with
nucleolin (Figure 3A). When wild type ErbB1 was co-expressed
with nucleolin and DTK, nucleolin induced ErbB1 and ErbB1
DTK mutant phosphorylation. The DTK although binds
nucleolin, do not undergo nucleolin-associated phosphorylation
unless wild type ErbB1 is present (Figure 3A). Nucleolin however,
induces dimerization of the DTK as evident by the crosslinking
experiments (Figure 3B). Thus, nucleolin-induced ErbB1 phos-
phorylation depends on receptor dimerization and functional
receptor tyrosine kinase domain.
To further study the importance of the receptor NLS region for
nucleolin interaction new expression vectors of chimeric proteins
were generated as shown in the scheme (Figure 4A). The chimeric
proteins were examined for their ability to bind nucleolin by co-
immunoprecipitation. As shown in Figure 4B, only the chimeric
protein that contains the NLS was precipitated by nucleolin. The
chimeric protein that contained only the transmembrane domain
failed to be precipitated by nucleolin. These results further support
the importance of the NLS region of ErbB1 for nucleolin
interaction.
Analysis of nucleolin domains responsible for the
interaction with ErbB receptors
Previously we have demonstrated that Glutathione-S-trans-
ferase-ErbB4 (GST-ErbB4) pulled down nucleolin. Further
analysis has shown that nucleolin interacts and activates the
four ErbB receptors in a ligand independent manner [28]. To
further investigate the interactions between ErbB and nucleolin
we used the pull down assay. A chimeric fusion protein of
GST and ErbB4 cytoplasmic tail (GST-ErbB4) was used as a
bait to pull down nucleolin mutants. Several deletion mutants
of nucleolin were generated. The scheme of the designed
deletion mutants is presented in Figure 5A. Cell extracts were
prepared from HEK-293T cells transfected with the expression
vectors encoding the wild type and the various nucleolin
mutants N-ter, 212, RBD, GAR, all fused to GFP. As shown
in Figure 5B, GST-ErbB4 pulled down wild type nucleolin and
the 212 C-terminal amino acids mutant but not the N-terminal
mutant. Moreover the GST-ErbB4 pulled down significantly
less effectively, both the RBD and the GAR mutants, which
are part of the 212 C-terminal portion of nucleolin. The results
indicate that the C-terminal region of nucleolin is important for
its binding to the cytoplasmic tail of ErbB4 receptor. To
further examine the interaction between ErbB1 and nucleolin
we have used co immunoprecipitation experiments on HEK-
293 cells stably over expressing ErbB1 receptor transfected with
the various nucleolin mutant expression vectors. As shown in
Figure 5C, ErbB1 was precipitated effectively by both full-
length nucleolin and 212 C-terminal amino acids mutant, less
effectively to GAR and RBD mutants, but not by the N-
terminal mutant of nucleolin. These results further support the
importance of this nucleolin region (212 mutant) for the
interaction with ErbB1 receptors.
To determine whether the 212 C-terminal amino acids mutant
of nucleolin affects ErbB1 tyrosine phosphorylation, we co-
expressed ErbB1 protein with or without nucleolin or the 212
C-terminal amino acids mutant, in HEK-293 cells. Both nucleolin
and 212 C-terminal amino acids mutant of nucleolin when co-
expressed with ErbB1 induced receptor phosphorylation even in
the absence of EGF. This was evident using anti-phosphotyrosine
antibodies that recognize phosphorylated tyrosines (Figure 6A). As
control for receptor phosphorylation, cells were stimulated with
EGF as indicated. Expression of nucleolin N-ter, RBD and GAR
mutants with ErbB1 failed to induce receptor phosphoryaltion
ErbB/Nucleolin Interactions
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amino acids of nucleolin are sufficient to induce ErbB1
phosphorylation. To address the possibility that the 212 C-
terminal amino acids of nucleolin induces the competence of
ErbB1 dimerization and trans-auto-phosphorylation, we examined
the effect of the 212 C-terminal amino acids of nucleolin on
receptor dimerization, which was determined by covalent cross-
linking (Figure 6B). Clearly, ligand-independent formation of
ErbB1 dimers is potentiated following the expression of nucleolin
and 212 C-terminal amino acids of nucleolin. As a control
homodimerization of the ErbB1 receptors was induced by the
ligand EGF. These observations may suggest that the receptor
phosphorylation induced by 212 C-terminal amino acids of
nucleolin may result due to receptor dimerization.
Analysis of ErbB1 and nucleolin domains localization and
anchorage-independent growth in HEK-293 over
expressing cells
Since the 212 C-terminal amino acid of nucleolin mediated
similar effects as the full-length protein we next examined the
localization of these two proteins. HEK-293T cells were
transiently co-transfected with GFP-ErbB1 and either pDsRed
empty vector, pDsRed-nucleolin, pDsRed-N-ter or pDsRed-212
C-ter, their sub cellular localization was studied 48 hours later by
confocal microscopy. As exemplified in Figure 7 and in agreement
with previous reports [34], GFP-ErbB1 was localized to the
plasma membrane and to the cytoplasm vesicular compartment.
Full-length nucleolin was mainly localized to the nucleus as well as
to the plasma membrane. GFP-ErbB1 and pDsRed-nucleulin co-
Figure 1. Analysis of the ErbB1 regions important for ErbB1 nucleolin interaction. (A) Schematic presentation of ErbB1 deletion mutants.
(B) Cells were co-transfected with pEGFP-nucleolin-Myc and the indicated ErbB1 mutant expression vectors. The resulting cell lysates were subjected
to immunoprecipitation with anti-Myc antibodies and immunoblotted with monoclonal antibody directed to the extracellular portion of ErbB1 (anti-
111). Total cell lysates are shown.
doi:10.1371/journal.pone.0006128.g001
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and DsRed-N-ter showed no co-localization since DsRed-N-ter
was localized exclusively to the nucleus whereas ErbB1 was
excluded from the same compartment. Interestingly, DsRed-212-
C-ter co-localized with GFP-ErbB1 at the cell surface. These
results are in agreement with the above-described interactions and
further support the notion that nucleolin 212 C-terminal amino
acids are sufficient for the interaction with ErbB1 on the cell
surface.
In order to further examine the effect of 212 C-terminal amino
acids of nucleolin on ErbB1-mediated responses we prepared
HEK-293 cells stably expressing empty vector, ErbB1, 212-C-ter
or ErbB1 together with 212-C-ter. In order to assess effects of
ErbB1 and 212-C-ter on colony formation, HEK-293 stable clones
Figure 2. The DNLS mutant of ErbB1 is not activated in the presence of nucleolin or in the presence of its ligand, EGF. HEK-293T cells
were co-transfected with pEGFP-nucleolin-Myc and either the wild type ErbB1 or DNLS ErbB1 deletion mutant expression vectors. Following 20
minutes serum deprivation, cells were treated with or without EGF (100 ng/ml) for 10 minutes. (A) Cell lysates were immunoblotted with monoclonal
antibody anti PY20. As control cell lysates were immunoblotted with polyclonal antibody to ErbB1, or monoclonal antibody anti Myc as indicated. (B)
Cell lysates were incubated with BS3 cross linker and immunobloted with polyclonal antibody anti ErbB1.
doi:10.1371/journal.pone.0006128.g002
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number and size of colonies were then estimated from three
individual clones. Results of a typical experiment are shown in
Figure 8. HEK-293 cells overexpressing either ErbB1 or 212-C-
ter, formed relatively low number of colonies. However, HEK-293
cells overexpressing ErbB1 and 212-C-ter, formed relatively
significantly high number of colonies in soft agar (p,0.001). Pools
of mock-transfected HEK-293 cells were plated in soft agar as a
control and showed relatively low number of colonies in soft agar
(Figure 8B). These results indicate that the 212-C-ter interaction
with ErbB 1 is functional in mediating the anchorage-independent
growth of the cells overexpressing both ErbB1 and 212-C-ter.
Discussion
The ErbB receptors are activated by their cognate growth
factors under normal physiological conditions [14,35]. Ligand
binding to ErbB receptors induces the formation of receptor
homo- and hetero-dimers and activation of the intrinsic kinase
domain, resulting in phosphorylation on specific tyrosine residues
within the cytoplasmic tail. These phosphorylated residues serve as
docking sites for a range of proteins, the recruitment of which leads
to the activation of intracellular signaling pathways [13]. Recently,
we have demonstrated that cell-surface ErbB receptors, interact
with nucleolin via their cytoplasmic tail [28]. Nucleolin is a
ubiquitous, nonhistone, nucleolar, multifunctional phosphoprotein
that is also overexpressed in cancer cells [16,36]. It was
demonstrated that nucleolin not only interacts with ErbB proteins
but may also affect their activation [28]. Overexpression of ErbB1
and nucleolin may lead to receptor dimerization, phosphorylation
and to anchorage independent growth [28]. Based on these results
we have previously suggested that nucleolin may modulate ErbB
receptors activities.
In the present study, we characterized the protein domains
responsible for this interaction and for receptor activation. We
found that the interaction between nucleolin and ErbB1 depends
on the NLS domain of ErbB1 (RRRHIVRKRTLRR (amino acids
669–681)) (Figures 1–4). This region is known to regulate ErbB1
activity, since it mediates the nuclear localization of EGFR [33] as
well as receptor kinase activation [32]. However, other studies
demonstrated that mutation of EGFR tripartite NLS or deletion of
the ErbB2 tripartite NLS did not affect receptor protein
membrane localization and activation of MAPK signaling [37].
In our study we demonstrated that upon nucleolin or ligand
stimulation the DNLS mutant of ErbB1 does not undergo
phosphorylation (Figure 4A). However, further examination of
the receptor dimerization using BS3 crosslinker, demonstrated that
EGF can induce DNLS mutant dimerization. Studies have shown
that upon ligand binding the dimerization process starts from the
extracellular region of EGFR [38]. Hence, by using the cross
linker we observed receptor dimerization, although the dimeriza-
tion/activation process was not completed, as demonstrated by the
lack of phosphorylation (Figure 4). Thus, EGF but not nucleolin
can induce the dimerization of DNLS mutant. These results
support our findings that the DNLS ErbB1 mutant does not
interact with nucleolin. In addition, using expression vectors of
TM-NLS compared to TM mutants further demonstrate the
importance of the NLS for nucleolin interaction. Interestingly, the
NLS region of ErbB1 and ErbB4 are highly conserved
(RRKSIKKKRALRR amino acids 666–678 in ErbB4) which
Figure 3. The DTK mutant of ErbB1 does not undergo nucleolin-mediated activation unless wild type ErbB1 is present. HEK-293T cells
were co-transfected with pEGFP-nucleolin-myc and the wild type ErbB1 or DTK ErbB1 deletion mutant or both expression vectors. Following 20
minutes starvation cells were treated with EGF (100 ng/ml) for 10 minutes. (A) Cell lysates were immunoblotted with monoclonal antibody anti PY20.
As control cell lysates were immunoblotted with polyclonal antibody to ErbB1, or monoclonal antibody anti Myc as indicated. (B) Cell lysates were
incubated with BS3 cross linker and immunoblotted with polyclonal antibody to ErbB1.
doi:10.1371/journal.pone.0006128.g003
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ingly, our present results strongly suggest that the NLS region of
the receptor is the nucleolin-binding domain. Using the DTK
ErbB1 mutant we demonstrated that the tyrosine kinase domain,
although not essential for ErbB1/nucleolin interaction, is crucial
for ErbB1 activation induced by nucleolin. Our results further
indicate that DTK undergoes EGF or nucleolin induced
dimerization but not phosphorylation indicating that nucleolin-
mediated receptor activation depends on the receptor kinase
domain activity (Figure 3).
Further examination of the nucleolin domains responsible for
this interaction and for receptor activation was performed. We
found that the C-terminal 212 amino acids of nucleolin (Nuc-212)
are necessary for the interaction between nucleolin and ErbB4 or
ErbB1 (Figure 5). We have also demonstrated that the last 212
amino acids of nucleolin are sufficient for the activation of ErbB1
receptor (Figure 5). These amino acids are comprised of two
distinct regions, RBD and GAR. Neither RBD nor GAR
effectively interacted with either ErbB4 or ErbB1 (Figure 5), ergo
the entire sequence is important for the stable interaction with
ErbB receptors. A specific interaction of (Nuc-212) with the Mo-
MuLV Gag precursor was previously demonstrated. This binding
of (Nuc-212) resulted in a strong inhibition of virion assembly or
release in vivo [39]. However, 212 C-ter nucleolin (Nuc-212) binds
and activates ErbB1 in a similar manner as the full-length
nucleolin thus, indicating that this region is sufficient for binding
and activation.
Nucleolin contains three main structural domains: N-terminal
region containing several long stretches of acidic residues; central
globular domain containing four RNA binding sites; C-terminal
domain known as arginine-glycine rich domain (GAR domain). As
previously described the 212-C-ter mutant we used is comprised of
the fourth RBD and the GAR domains. Upon stimulation of cell
proliferation, cytoplasmic nucleolin is translocated to the cell
surface [40]. Cell surface nucleolin serves as a low affinity receptor
for HIV-1 and binds various growth factors via interaction with its
GAR domain (i.e. midkine, pleiotrophin (PTN) and lactoferrin)
[22,41–43]. The GAR domain was further demonstrated to be the
binding site of HB-19 pseudopeptide which was demonstrated to
block nucleolin function as a low affinity receptor on the cell
surface [41,42]. Cell surface nucleolin could shuttle ligands
between the cell surface and the nucleus thus acting as a mediator
for the extracellular regulation of nuclear events [22,23,44]. In
addition, accumulating data suggest that nucleolin binds other
proteins such as the glucocorticoid receptor [45] and protein
tyrosine phosphatase-sigma [46] and affects their activities. In the
present study we demonstrate that the 212 C-terminal amino acids
of nucleolin are sufficient to induce ErbB1 phosphorylation and
Figure 4. The NLS of ErbB1 is important for ErbB1 nucleolin interaction. (A) Schematic presentation of the chimeric protein expression
vectors. (B) Cells were transfected with nucleolin-myc and either pEGFP (empty vector), pEGFP-TM-NLS or pEGFP-TM expression vectors. The resulting
cell lysates were subjected to fractionation and the pellets were subjected to immunoprecipitation with anti-Myc antibodies and immunoblotted
with anti GFP antibodies. As control, total cell lysates were blotted with anti-GFP and anti-Myc antibodies.
doi:10.1371/journal.pone.0006128.g004
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ErbB1 and 212-C-ter nucleolin co-localize on the cell surface
(Figure 7). Moreover this interaction is functional as it is sufficient
to increase growth in soft agar (Figure 8). Taken together our
results, we suggest that the 212 C-terminal amino acids of
nucleolin bind to the NLS of ErbB1 on the cell surface. The
interaction induces dimerization of ErbB1, resulting in phosphor-
ylation through the tyrosine kinase domain.
There are increasing evidences that nucleolin expression on
the cell surface is implicated in growth of tumor cells.
Inhibition of nucleolin activity results in cell growth inhibition
[24,25]. It was demonstrated in several studies that AS1411, a
quadruplex-forming oligonucleotide aptamer, targets nucleolin
and inhibits cancer cells growth [26,27]. In addition, ErbB
receptor tyrosine kinases are major contributors to malignant
transformation and they are frequently overexpressed in a
variety of human carcinomas [47]. Thus, our results may
suggest that the significance of nucleolin expression on the cell
surface of tumor cell lines is to increase receptor-mediated
activities.
Figure 5. The 212 C-terminal aa of nucleolin are important for nucleolin ErbB interaction. GST pull-down assay showing ErbB4 interaction
with nucleolin and nucleolin mutants. (A) Schematic presentation of nucleolin deletion mutants. (B) HEK-293T cells were transfected with pEGFP
(empty vector), pEGFP-nucleolin-myc or pEGFP-nucleolin-myc mutant expression vectors. The resulting cell lysates were incubated with immobilized
GST-ErbB4 or GST. Proteins retained on the beads were resolved by SDS-PAGE and then processed for Western blot using a monoclonal antibody
anti- GFP. (C) The resulting cell lysates were subjected to fractionation and the pellets were subjected to immunoprecipitation with anti-GFP antibody
and immunoblotted with anti ErbB1 polyclonal antibody.
doi:10.1371/journal.pone.0006128.g005
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Materials and Buffers
Human recombinant EGF was purchased from Boehringer
Mannheim. Polyclonal rabbit anti- ErbB1 antibodies, monoclonal
mouse anti-phosphotyrosine (PY20), mouse anti-GFP (B-2) were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Polyclonal rabbit anti phosphorylated ErbB1 (Tyr1068)
were purchased from Cell Signaling technology. Monoclonal
mouse anti N’ terminal EGFR (Ab 10) were from NeoMarkers
(Lab Vision corporation). Monoclonal mouse anti c-Myc (9E10)
was donated by Dr. Altchuler Yoram the Hebrew University,
Israel. All other reagents were from Sigma. HNTG buffer
contained 20 mM HEPES (pH 7.5), 150 mM NaCl, 0.1% Triton
X-100 and 10% glycerol. Solubilization buffer contained 50 mM
HEPES (pH 7.5), 150 mM NaCl, 1% Triton X-100, 1 mM
EGTA, 1 mM EDTA, 1.5 mM MgCl2, 10% glycerol, 2 mM
sodium vanadate, 1 mM phenylmethylsulfonylfluoride, 10 mg/ml
aprotanin and 10 mg/ml leupeptin. Pull Down buffer contained
50 mM TRIS-HCl (pH 7.6), 20 mM MgCl2, 150 mM NaCl,
1 mM DTT, 2 mM sodium vanadate, 1 mM phenylmethylsulfo-
nylfluoride, 10 mg/ml aprotanin, 10 mg/ml leupeptin, 0.5% NP40,
5 mg/ml pepstatine and 1 mM Benzamidine. Binding buffer
contained 50 mM TRIS-HCl (pH 7.6), 10 mM MgCl2, 100 mM
NaCl, 0.5 mM DTT and 0.5 mg/ml BSA.
Cell lines
HEK-293, HEK-293T cell lines were grown in Dulbecco’s
modified Eagle’s (DMEM) supplemented with 10% fetal bovine
serum. Cells were transfected using jetPEI (Poly plus transfection,
USA) or using calcium phosphate precipitation. Cell lysates were
prepared 48 hours following transfection as described. The HEK-
293 cells were used for stably expressing the ErbB-1 receptor and
nucleolin c-terminal 212 amino acids (212). Expression vector
pEGFP-ErbB-1 containing the coding region of ErbB-1 and
expression vector pcDNA3-Myc-212 containing the 212 c-
terminal region of nucleolin were introduced by CaPO4
transfection into HEK-293 cells either alone or together. The
neomycin (G418) resistant colonies were checked for ErbB-1 or
nucleolin-212 expression and several colonies (at least 4 from each
combination) were selected for further analysis. Expression vector
pcDNA3-ErbB-1 containing the coding region of ErbB-1 was
introduced by CaPO4 transfection into HEK-293 cells. The
neomycin (G418) resistant colonies were examined for ErbB-1
expression.
DNA constructs
A C’ terminally myc-tagged mouse nucleolin (pMT21-myc-
nucleolin) was generously provided by Dr. Bacharach E. (Tel-Aviv
University, Israel). Nucleolin-myc cDNA was amplified using the
Figure 6. The 212 C-terminal aa of nucleolin are sufficient to induce ErbB1 phosphorylation and dimerization. (A) Cells were
transiently co-transfected with expression vector of ErbB1 receptor and with either pEGFP, pEGFP-nucleolin-Myc (GFP-NCL) or pEGFP-212-nucleolin-
Myc (GFP-212) mutants. Following 20 minutes serum deprivation, cells were treated with or without EGF 100 ng/ml for 10 minutes. Cell lysates were
immunobloted with monoclonal antibody PY20. As a control lysates were immunoblotted with polyclonal antibody anti ErbB1 as indicated. (B) Cells
were transiently co-transfected with expression vector of ErbB1 receptor and with either pEGFP, pEGFP-nucleolin-Myc (GFP-NCL) or pEGFP-212-
nucleolin-myc (GFP-212) mutants. Following 20 minutes serum deprivation, cells were treated with or without EGF 100 ng/ml for 10 minutes. Cell
lysates were incubated with BS3 cross linker and immunobloted with polyclonal antibody anti ErbB1.
doi:10.1371/journal.pone.0006128.g006
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GAAGCTCGCG and 59CGAACCATGATGGCTCGAAT-
CAC. The amplified fragment was digested with EcoRI and
XbaI and cloned into pcDNA3 expression vector. Next we
generated several nucleolin mutants using PCR amplification,
digestion EcoRI and EcoRV and cloning into EcoRI and EcoRV
digested pcDNA3-nucleolin-myc expression vector. N’ terminal
primers were: 59CGGAATTCGCCACCATGGT-
GAAGCTCGCG and 59GATATCGTTGCACTTAGG. 212
fragment (the C-terminal 212 amino acids of nucleolin) primers
were: 59CCGGAATTCGCCACCATGACAAAAGAACTC and
59CGAACCATGATGGCTCGAATCAC. RNA binding domain
4 (RBD) primers were: 59CCGGAATTCGCCACCATGA-
CAAAAGAACTC and 59GATATCCCCTTAGGTTGG.
GAR primers were: 59 CCGGAATTCGCCACCATGGGR-
GAAGGGTG and 59GGAACCATGATGGCTCGAATCAC.
In order to generate GFP-fused nucleolin-myc or nucleolin
mutants-myc expression vectors, the pcDNA3-nucleolin-myc
vector or pcDNA3-nucleolin-myc mutants were digested with
EcoRI and ApaI and cloned into pEGFP-C2 and DsRed-C2
expression vectors.
The following ErbB1 mutants were generated: Dcyt1 fragment
(1–667 aa) was amplified using PCR, digested with BstEII and
XhoI and cloned into pcDNA3-ErbB1. Dcyt1 primers were:
59TCGGGGAGCAGCGATGCGAC and
59CCGCTCGAGCTATTACATGAAGAGGCCGATCCC.
Dcyt2 fragment (1–1076 aa) was amplified using PCR, digested
with BstEII and XhoI and cloned into pcDNA3-ErbB1. Dcyt2
primers were:59 TCGGGGAGCAGCGATGCGAC and
59 CCGCTCGAGTTACTATGAGCTGTATCGCTGCAA-
GAAG. Dcyt3 fragment (1–984 aa) was amplified using PCR,
digested with BstEII and XhoI and cloned into pcDNA3-ErbB1.
Dcyt3 primers were: 59 TCGGGGAGCAGCGATGCGAC and
59 CCCTCGAGTTACTAAAGGTAGCGCTGGGGGTCTC-
GG. In order to delete the tyrosine kinase domain (712–968 aa)
DTK, pcDNA3-ErbB1 was digested with EcoRI. The EcoRI
fragment encoding amino acids 1–711 and 969–1211 were cloned
in pCDNA3 expression vector.
In order to delete the Nuclear Localization Signal (669–681 aa),
DNLS fragment was amplified using 2 sets of primers: 59
TGGGTACCCTGCTGCAGGAGAGGGAGC, 59 CTCCGT-
GGTCATGCTCCAAT and
59 AATACGACTCACTATAG, 59 ACGGTACCCATGAA-
GAGGCCGATGCCAG.
The 2 fragments were digested with KpnI and BstEII or EcoRV
respectively. The two fragments were cloned into pcDNA3-ErbB1
digested with BstEII and EcoRV.
GFP-TM-NLS mutant, which contains the signal peptide (aa 1–
25), the trans membrane and the NLS domains (aa 646–681) was
amplified using 2 sets of primers: 59GAAGATCTGCCACCAC-
CATGCGACCCTCCG, 59CAGTGGCGATCAGAGCCC-
GACTCG and
59 GGGCTCTGATCGCCACTGGGATG, 59GGAATTCC-
CTCCGCAGCGTGC.
The 2 PCR products were used as template for a third
amplification using the following primers: 59GAAGATCTGC-
CACCACCATGCGACCCTCCG and
59GGAATTCCCTCCGCAGCGTGC. The PCR product was
digested with EcoRI and BglII and cloned into GFP-N2
expression vector digested with BstEII and EcoRV.
GFP-TM mutant, which contains the signal peptide (aa 1–25),
and the trans membrane domain (aa 646–668) was amplified using
Figure 7. Cellular distribution of ErbB1 and nucleolin mutants. HEK-293T cells were transfected with EGFP-ErbB1 and either pDsRed, pDsRed
-nucleolin, pDsRed -N-ter or pDsRed -212-C-ter. 48 h following transfection cells were fixed and subjected to confocal microscopy analysis. GFP-ErbB1
is visualized in green and pDsRed expression vectors are seen in red. Representative cells are presented.
doi:10.1371/journal.pone.0006128.g007
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GACCCTCCG, 59 CAGTGGCGATCAGAGCCCGACTCG
and
59 GGGCTCTGATCGCCACTGGGATG, 59 GGAATTC-
CATGAAGAGGCCG.
The 2 PCR products were used as template for a third
amplification using the following primers: 59GAAGATCTGC-
CACCACCATGCGACCCTCCG and 59GGAATTCCAT-
GAAGAGGCCG. The PCR product was digested with EcoRI
and BglII and cloned into GFP-N2 expression vector digested with
BstEII and EcoRV.
Lysate Preparation, Immunoprecipitation and
Immunoblotting
Cells were exposed to the indicated stimuli. After treatment,
cells were solubilized in lysis buffer. Lysates were cleared by
centrifugation. For direct electrophoretic analysis, boiling gel
sample buffer was added to cell lysates For other experiments,
antibodies were first coupled to anti-mouse IgG agarose (for
monoclonal antibodies) or protein A-sepharose (for polyclonal
antibodies) for 1 h at RT. Then the proteins in the lysate
supernatant were immunoprecipitated with aliquots of the beads-
antibody complexes for 2 h at 4uC. The immunoprecipitates were
washed three times with HNTG, resolved by SDS-polyacrylamide
gel electrophoresis (PAGE) through 7.5% gels and electrophoret-
ically transferred to nitrocellulose membrane. Membranes were
blocked for 1 h in TBST buffer (0.02 M Tris-HCl pH 7.5, 0.15 M
NaCl, and 0.05% Tween 20) containing 6% milk, blotted with
1 mg/ml primary antibodies for 2 h, followed by 0.5 mg/ml
secondary antibody linked to horseradish peroxidase. Immunore-
active bands were detected with the enhanced chemiluminescence
reagent (Amersham Corp, Buckinghamshire, UK). For cell
fractionation, cells were homogenized, and the supernatant
(soluble proteins) and the pellet (insoluble proteins) fractions were
obtained by centrifugation (100,0006g, 30 min, 4uC) [48].
Figure 8. Nucleolin-212-C-ter mutant and ErbB1- induced anchorage-independent growth. (A) HEK-293 cells stably expressing empty
vector (not shown), ErbB1, nucleolin-212-C-ter or ErbB1 and nucleolin-212-C-ter were seeded in soft agar (4000 cells/well in 96 well plates) in medium
containing 10% FBS, 0.3% agar, in the presence of 100 ng/ml EGF. The extent colony formation was determined 2 weeks later. Cells were dyed with
MTT and the wells were photographed and colonies were counted. Representative image is presented. (B) Results were quantified using image
analyzer program Image pro-Plus. The results are presented as the number of colonies at size larger then 0.01 mm
2. Note that nucleolin-212-C-
ter+ErbB1 but not each protein alone induced significantly more colonies (p,0.001). Results are the mean 6 SD 6 determinations from each clone (3
clones from each stable cell line). Each experiment was repeated twice with similar results.
doi:10.1371/journal.pone.0006128.g008
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itation.
Cross-linking
Cross-linking experiments were performed by addition of 2 mM
bis (sulfosuccinimidyl) suberate (BS3), to the lysis buffer for
20 min on ice. The chemical crosslinking reaction was stopped by
adding 50 mM Glycine and the samples were resolved by SDS-
PAGE [15].
GST Pull-Down Assay
To characterize proteins that interact with the cytoplasmic tail
of ErbB4, a GST-ErbB4 column was generated by absorbing
20 ml of GST-ErbB4 -producing E. coli lysate (resulting from a 1-
liter culture) to 1 ml of glutathione-Sepharose (Sigma). A similar
column was prepared from GST-producing E. coli. PC12 cell
lysate was prepared and a total of 2 mg protein was loaded on
GST or GST-ErbB4 columns (in the presence of 0.5 ml binding
buffer) for 2 h at 4uC. After the incubation the beads were washed
three times with binding buffer. The GST and GST-ErbB4 bound
proteins were eluted in boiling sample buffer and resolved by SDS-
PAGE through 7.5% gels and electrophoretically transferred to
nitrocellulose membrane for immunoblot analysis.
Imaging
HEK-293T cells were plated on glass cover slips placed in 6
wells plates at a density of 2610
5 cells perwell for 24 h before
transfection. Cells were transfected with GFP-ErbB1 and either
DsRed, DsRed-NCL, DsRed-Nter or DsRed-212. 48 hours later,
cells were fixed by 4% paraformaldehyde at room temperature for
30 min. Cells were examined by fluorescent microscopy at 636
magnification with Zeiss 510 confocal microscopy.
Soft Agar Assay
Cells were seeded at a density of 4000 cells/well in 96 well plates
in DMEM containing 10% FBS. The cells were mixed with
0.05 ml (per each well) of 0.33% noble agar, and the mixture was
poured onto a layer of 0.05 ml 1% noble agar in DMEM
containing 10% FBS. The upper layer of the agar was covered
with 0.1 ml of medium. Assays were performed in at least six
repeats. The number and sizes of the colonies were estimated on
day 14, using a binocular and a light microscope with the image
analyzer program Image pro-Plus. Results are the mean6SD 6
determinations of each of the clones that were used (3 stable clones
from each transfection).
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